Latest Breaking News On - Mortality worldwide - Page 25 : comparemela.com

SYDNEY, Nov. 21, 2022 /PRNewswire/ Highlights Clarity's fifth successful Investigational New Drug (IND) application with the United States Food and Drug Administration (US FDA), opening up therapeutic applications for SAR-Bombesin A total of six products with both the diagnostic and therapeutic applications for SARTATE, SAR-bisPSMA and SAR Bombesin are now under IND for US clinical trials First therapeutic clinical program for SAR-Bombesin will be in PSMA negative metastatic castrate resistant prostate cancer, an area of high unmet need Clarity Pharmaceuticals(ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, announces the approval of its Investigational New Drug (IND) application by the United States Food and Drug Administration (US FDA) to evaluate its SAR-Bombesin product for identification and treatment of metastatic castrate-resi

United statesNew south walesAlan taylorGuggerm bombesinClarity pharmaceuticalsNational cancer instituteTechnology platformDrug administrationCancer statistics centerAmerican cancer societyInvestigational new drugUnited states foodExecutive chairmanTargeted copper theranosticGastrin releasing peptideSpecific membrane antigen uptake